Evaluating the potential bioactivity of a novel compound ER1626

about

Evaluating the potential bioactivity of a novel compound ER1626

Item

http://www.wikidata.org/entity/Q28539181

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evaluating the potential bioactivity of a novel compound ER1626

@ast

Evaluating the potential bioactivity of a novel compound ER1626

@en

Evaluating the potential bioactivity of a novel compound ER1626

@nl

type

Item

label

Evaluating the potential bioactivity of a novel compound ER1626

@ast

Evaluating the potential bioactivity of a novel compound ER1626

@en

Evaluating the potential bioactivity of a novel compound ER1626

@nl

prefLabel

Evaluating the potential bioactivity of a novel compound ER1626

@ast

Evaluating the potential bioactivity of a novel compound ER1626

@en

Evaluating the potential bioactivity of a novel compound ER1626

@nl

P1476

Evaluating the potential bioactivity of a novel compound ER1626

@en

P2093

Hongyi Liu

http://www.w3.org/2001/XMLSchema#string

Lijun Wang

http://www.w3.org/2001/XMLSchema#string

Tianling Wang

http://www.w3.org/2001/XMLSchema#string

Yanyan Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Estrogen receptor transcription and transactivation: Basic aspects of estrogen action.

Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

The biology of VEGF and its receptors

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Estrogen carcinogenesis in breast cancer

Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination

P304

e86509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0086509

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hong Xiao

Hua Xiang

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259961276

http://www.w3.org/2001/XMLSchema#string

P698

24475135

http://www.w3.org/2001/XMLSchema#string

P932

3903524

http://www.w3.org/2001/XMLSchema#string